This site is intended for healthcare professionals

Padsevonil in ARISE Phase IIb trial does not meet statistical significance for treatment of focal-onset seizures . UCB

Read time: 1 mins
Published:17th Mar 2020
UCB, a global biopharmaceutical company, announced top-line results from ARISE (NCT03373383), the first of two adequate and well-controlled studies, investigating the efficacy and safety of padsevonil for the treatment of observable focal-onset seizures in adults with drug-resistant epilepsy. This randomized, double-blind, placebo-controlled Phase IIb study did not reach statistical significance for either of the primary endpoints, change from Baseline in observable focal-onset seizure frequency and 75 percent responder rate for padsevonil compared with placebo over the 12-week maintenance period. Padsevonil was generally well-tolerated and its safety profile was consistent with that seen in earlier studies. ARISE is the first of two adequate and well-controlled studies which seek to investigate the safety and efficacy of UCB’s padsevonil in the treatment of focal-onset seizures in patients with highly treatment-resistant epilepsy. The impact of the ARISE results on the second, ongoing study, UCB0092 (DUET), is currently being evaluated.
Condition: Epilepsy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.